We chose this model due to observations that the PIK3CA mutation enhances COX-2 expression and promotes tumor proliferation via autocrine signaling, possibly informing eventual selection of patient populations that may be responsive to TPST-1495 therapy (22). The gene discussed is PTGS2; the disease is neoplasm.